ianalumab ianalumab ianalumab (inn; development code vay736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, sjögren syndrome, and systemic lupus erythematosus. ianalumabmonoclonal antibodytype?sourcehumantargetbaff receptorclinical dataother namesvay736atc codenoneidentifierscas number1929549-92-7uniizn2gq3ii96keggd12151 this drug is being developed by novartis. as of 2021, ianalumab is undergoing phase ii/iii trials.